# Pizarra — PT-pseudo_20a7e91c494c (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_20a7e91c494c
Task: 1

Encounter: Urology - outpatient on 13 Feb 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 4.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 0.63 ng/mL/yr
  - Prior PSA: 3.9 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7866596 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30), Atrial fibrillation
  - Problem list / PMHx: Obesity (BMI >30), Atrial fibrillation
  - Current medication: metoprolol
  - Allergies: NKA
  - Additional notes: PSA 4.5 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 73 mL. csPCa 0.79.

Vitals: weight 88 kg, height 176 cm, BMI 28.4, BP 114/76 mmHg, HR 90 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2008).

Chief complaint: Rising PSA to 4.5 ng/mL prompts clinical reassessment following a prior positive biopsy.

History: A 71-year-old, retired postal worker, lives in a ground-floor apartment with his partner, and is divorced. He manages moderate lower urinary tract symptoms (IPSS 11/35) through watchful waiting, complemented by a daily 45-minute walking regimen and weekly alcohol consumption of approximately 23 units. Medical background includes well-controlled atrial fibrillation, currently treated with metoprolol, alongside remote right knee arthroscopy (2015) and managed hypothyroidism with recent endocrine follow-up. Obesity (BMI >30) is noted. He is an ex-smoker (31 pack-yr, quit 2008), attends biannual podiatry visits, and routinely commutes over an hour by train to this clinic without difficulty. He explicitly denies bone pain, haematuria, or unexplained weight loss.

Physical examination: DRE — prostate symmetrically enlarged, smooth and firm texture, absent nodules or asymmetry. General survey shows blood pressure at 114/76 mmHg with a regular heart rate of 90 bpm. Abdominal palpation yields a soft, non-tender field, free of masses or organomegaly.

Patient info: retired postal worker; Divorced; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 23 units / week; exercise Walking 45 min/day; IPSS score: 11/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care; Endocrine — thyroid screening.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.47 +/- 0.19   (95% CI 0.10-0.85)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.19  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current findings (PI-RADS 4, rising PSA), warrants a re-biopsy or surveillance decision. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA 4.5 ng/mL, PI-RADS 4, prior positive biopsy, and csPCa probability 0.7866596. It cannot weigh the qualitative aspects of the mpMRI report prose, the specific PSA velocity (0.63 ng/mL/yr), or the context of the prior positive biopsy status relative to the current PI-RADS 4 finding.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.47 +/- 0.19. The wide epistemic error bar (dp = 0.19) indicates the model is highly uncertain, meaning the suggestion is not strongly supported by the data. Furthermore, the guideline criterion states the decision hinges on retrieved documents, which the prior ignored, potentially leading to a decision that is insufficient for this specific clinical context.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion in the right peripheral zone, base/mid, measuring 16x14x12 mm. No evidence of extraprostatic extension or suspicious lymphadenopathy.
get_psa_trend
PSA trend: PSA increased from 1.9 ng/mL (Jul 2022) to 4.5 ng/mL (Feb 2025). The trend shows a significant rise over the period.
get_previous_notes
Previous notes: Prior biopsy status is documented as 'Positive'. The patient was under monitoring, with a urology re-evaluation arranged in Oct 2024 following a rising trend and prior positive biopsy.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the current information is sufficient to address the core decision points.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- Rising PSA trend: PSA increased from 1.9 ng/mL (Jul 2022) to 4.5 ng/mL (Feb 2025).
- Imaging finding: PI-RADS 4 lesion in the right peripheral zone, base/mid, which is a focal finding.
- Prior context: Prior biopsy was positive, and a re-evaluation was arranged due to the upward trend.

AGAINST Sampling this patient now:
- DRE finding: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly suggests that the rising PSA trend, combined with a PI-RADS 4 finding and a history of a prior positive biopsy, warrants further investigation.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, showing a significant rising PSA trend and a history of a prior positive biopsy alongside a PI-RADS 4 finding, strongly leans towards a biopsy recommendation.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA 4.5 ng/mL, PI-RADS 4, prior positive biopsy, and csPCa probability 0.7866596. It cannot weigh the qualitative aspects of the mpMRI report prose, the specific PSA velocity (0.63 ng/mL/yr), or the context of the prior positive biopsy status relative to the current PI-RADS 4 finding.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.47 +/- 0.19. The wide epistemic error bar (dp = 0.19) indicates the model is highly uncertain, meaning the suggestion is not strongly supported by the data. Furthermore, the guideline criterion states the decision hinges on retrieved documents, which the prior ignored, potentially leading to a decision that is insufficient for this specific clinical context.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion in the right peripheral zone, base/mid, measuring 16x14x12 mm. No evidence of extraprostatic extension or suspicious lymphadenopathy.
get_psa_trend
PSA trend: PSA increased from 1.9 ng/mL (Jul 2022) to 4.5 ng/mL (Feb 2025). The trend shows a significant rise over the period.
get_previous_notes
Previous notes: Prior biopsy status is documented as 'Positive'. The patient was under monitoring, with a urology re-evaluation arranged in Oct 2024 following a rising trend and prior positive biopsy.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the current information is sufficient to address the core decision points.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- Rising PSA trend: PSA increased from 1.9 ng/mL (Jul 2022) to 4.5 ng/mL (Feb 2025).
- Imaging finding: PI-RADS 4 lesion in the right peripheral zone, base/mid, which is a focal finding.
- Prior context: Prior biopsy was positive, and a re-evaluation was arranged due to the upward trend.

AGAINST Sampling this patient now:
- DRE finding: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly suggests that the rising PSA trend, combined with a PI-RADS 4 finding and a history of a prior positive biopsy, warrants further investigation.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fully addressed by retrieving the radiology report, PSA trend, and previous notes. The evidence strongly leans towards biopsy, despite the split between the prior and evidence positions.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The conference resolved a split between the statistical prior suggesting no biopsy and the retrieved evidence leaning towards biopsy. The evidence was supported by the rising PSA trend (from 1.9 to 4.5 ng/mL) and the PI-RADS 4 finding, which were not present in the initial panel. The decision to proceed with biopsy is based on the retrieved finding of the significant PSA rise and the history of a prior positive biopsy, which overturned the prior's suggestion to defer.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
